Cynata Therapeutics Ltd (CYP) - Total Liabilities
Based on the latest financial reports, Cynata Therapeutics Ltd (CYP) has total liabilities worth AU$1.22 Million AUD (≈ $860.53K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CYP asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Cynata Therapeutics Ltd - Total Liabilities Trend (2007–2025)
This chart illustrates how Cynata Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see CYP current and non-current assets.
Cynata Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Cynata Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ALLIANCE ONE INT
F:DM8
|
Germany | €3.13 Million |
|
Eagle Eye Solutions Group plc
LSE:EYE
|
UK | GBX18.07 Million |
|
Gabather AB (publ)
ST:GABA
|
Sweden | Skr4.20 Million |
|
PowerCompute, Inc.
NASDAQ:PWCM
|
USA | $21.56 Million |
|
Midwich Group PLC
LSE:MIDW
|
UK | GBX465.24 Million |
|
Induct AS
OL:INDCT
|
Norway | Nkr14.77 Million |
|
Sino Hua-An International Bhd
KLSE:2739
|
Malaysia | RM46.25 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Cynata Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Cynata Therapeutics Ltd balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cynata Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cynata Therapeutics Ltd (2007–2025)
The table below shows the annual total liabilities of Cynata Therapeutics Ltd from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$1.22 Million ≈ $860.53K |
+3.85% |
| 2024-06-30 | AU$1.17 Million ≈ $828.60K |
-48.19% |
| 2023-06-30 | AU$2.26 Million ≈ $1.60 Million |
-12.66% |
| 2022-06-30 | AU$2.59 Million ≈ $1.83 Million |
+61.57% |
| 2021-06-30 | AU$1.60 Million ≈ $1.13 Million |
+132.23% |
| 2020-06-30 | AU$689.74K ≈ $488.03K |
-46.04% |
| 2019-06-30 | AU$1.28 Million ≈ $904.46K |
+71.32% |
| 2018-06-30 | AU$746.15K ≈ $527.95K |
+91.52% |
| 2017-06-30 | AU$389.60K ≈ $275.66K |
-12.92% |
| 2016-06-30 | AU$447.38K ≈ $316.55K |
+19.18% |
| 2015-06-30 | AU$375.39K ≈ $265.61K |
+426.53% |
| 2014-06-30 | AU$71.30K ≈ $50.45K |
-52.37% |
| 2013-06-30 | AU$149.70K ≈ $105.92K |
-8.21% |
| 2012-06-30 | AU$163.09K ≈ $115.39K |
-33.68% |
| 2011-06-30 | AU$245.93K ≈ $174.01K |
-22.37% |
| 2010-06-30 | AU$316.81K ≈ $224.16K |
-30.87% |
| 2009-06-30 | AU$458.26K ≈ $324.25K |
+292.08% |
| 2008-06-30 | AU$116.88K ≈ $82.70K |
-20.58% |
| 2007-06-30 | AU$147.16K ≈ $104.13K |
-- |
About Cynata Therapeutics Ltd
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host … Read more